Sensation seeking has long been linked to risky behaviors in teens, but its role in eating-disorder psychopathology has been mixed. A 2026 study by Bogner and colleagues clarifies the picture in 400 German adolescents: sensation seeking matters for disordered eating, but the effects are moderated by weight status and emotional symptoms.1 Research Highlights Sensation seeking …
Lisdexamfetamine remains the only FDA-approved medication for binge-eating disorder — a serious condition affecting roughly 1.2% of adults. A 2026 human laboratory study by McKee and colleagues tests whether naltrexone/bupropion, already approved for obesity, reduces the food-reward mechanisms that drive binge episodes.1 Research Highlights Binge-eating disorder (BED) is the most common eating disorder in the …
Anorexia nervosa (AN), a severe mental disorder characterized by an intense fear of gaining weight and a distorted body image, remains a formidable challenge in psychiatric treatment. Recent research has shone a light on the potential of olanzapine, an atypical antipsychotic, in offering new hope through both systemic and innovative intranasal administration methods in animal …
Binge-eating disorder (BED), characterized by recurrent episodes of overeating without compensatory behaviors, is a significant global health concern. Lisdexamfetamine dimesylate (LDX), the only drug approved for moderate to severe BED, is showing promise not just in reducing episodes but also in altering brain function in ways previously not fully understood. Through a groundbreaking study, researchers …
In the quest to understand the alarming rise in obesity rates worldwide, recent research has pointed towards a surprising culprit: endocrine-disrupting chemicals (EDCs), such as bisphenol A (BPA) and phthalates. These chemicals, ubiquitous in our environment, have been linked to significant disturbances in the hormonal regulation of body mass and adipose tissue function. Highlights: Endocrine …
Belviq (Lorcaserin) is an anorectic medication manufactured by Arena Pharmaceuticals for the long-term management of obesity. As of 2012, the FDA approved lorcaserin to promote weight loss in adults with: BMIs exceeding 30 or BMIs exceeding 27 plus [at least] one weight-related medical comorbidity such as diabetes, hyperlipidemia, and/or hypertension. Upon administration, lorcaserin functions primarily …
According to National Health and Nutrition Examination surveys, over 2 out of 3 adults in the United States are overweight and/or obese. Excessive body weight and/or fat is understood to increase risk for numerous morbidities including: cancer, diabetes, heart disease, hypertension, sleep apnea, and stroke – and that’s just naming a few. Perhaps troubling is …